Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
370
NCT07137819
Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis
Phase: Phase 3
Role: Lead Sponsor
Start: Sep 4, 2024
Completion: Nov 30, 2027
NCT06934538
First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
Phase: Phase 1/2
Start: Jun 17, 2025
Completion: Jun 30, 2029